Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Deleterious effect of proton pump inhibitors on the disease course of cirrhosis.

Janka T, Tornai T, Borbély B, Tornai D, Altorjay I, Papp M, Vitális Z.

Eur J Gastroenterol Hepatol. 2019 Aug 27. doi: 10.1097/MEG.0000000000001499. [Epub ahead of print]

PMID:
31464790
2.

Optimized angiotensin-converting enzyme activity assay for the accurate diagnosis of sarcoidosis.

Csongrádi A, Enyedi A, Takács I, Végh T, Mányiné IS, Pólik Z, Altorjay IT, Balla J, Balla G, Édes I, Kappelmayer J, Tóth A, Papp Z, Fagyas M.

Clin Chem Lab Med. 2018 Jun 27;56(7):1117-1125. doi: 10.1515/cclm-2017-0837.

PMID:
29425104
3.

norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis.

Fickert P, Hirschfield GM, Denk G, Marschall HU, Altorjay I, Färkkilä M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter FP, Tornai I, Halilbasic E, Greinwald R, Pröls M, Manns MP, Trauner M; European PSC norUDCA Study Group.

J Hepatol. 2017 Sep;67(3):549-558. doi: 10.1016/j.jhep.2017.05.009. Epub 2017 May 18.

4.

Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.

Sipeki N, Davida L, Palyu E, Altorjay I, Harsfalvi J, Szalmas PA, Szabo Z, Veres G, Shums Z, Norman GL, Lakatos PL, Papp M.

World J Gastroenterol. 2015 Jun 14;21(22):6952-64. doi: 10.3748/wjg.v21.i22.6952.

5.

Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].

Papp M, Sipeki N, Tornai T, Altorjay I, Norman GL, Shums Z, Roggenbuck D, Fechner K, Stöcker W, Antal-Szalmas P, Veres G, Lakatos PL.

J Crohns Colitis. 2015 Aug;9(8):659-68. doi: 10.1093/ecco-jcc/jjv087. Epub 2015 May 12.

PMID:
25968583
6.

A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease.

Reinisch W, Altorjay I, Zsigmond F, Primas C, Vogelsang H, Novacek G, Reinisch S, Thomsen LL.

Scand J Gastroenterol. 2015;50(10):1226-33. doi: 10.3109/00365521.2015.1031168. Epub 2015 Apr 21.

7.

Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.

Dignass A, Stoynov S, Dorofeyev AE, Grigorieva GA, Tomsová E, Altorjay I, Tuculanu D, Bunganič I, Pokrotnieks J, Kupčinskas L, Dilger K, Greinwald R, Mueller R; International Budenofalk Study Group.

J Crohns Colitis. 2014 Sep;8(9):970-80. doi: 10.1016/j.crohns.2014.01.021. Epub 2014 Feb 15.

8.

Autologous dendritic cell based adoptive immunotherapy of patients with colorectal cancer-A phase I-II study.

Hunyadi J, András C, Szabó I, Szántó J, Szluha K, Sipka S, Kovács P, Kiss A, Szegedi G, Altorjay I, Sápy P, Antal-Szalmás P, Tóth L, Fazekas G, Rajnavölgyi É.

Pathol Oncol Res. 2014 Apr;20(2):357-65. doi: 10.1007/s12253-013-9704-3. Epub 2013 Oct 28.

PMID:
24163303
9.

A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED).

Reinisch W, Staun M, Tandon RK, Altorjay I, Thillainayagam AV, Gratzer C, Nijhawan S, Thomsen LL.

Am J Gastroenterol. 2013 Dec;108(12):1877-88. doi: 10.1038/ajg.2013.335. Epub 2013 Oct 22.

10.

High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis.

Papp M, Sipeki N, Vitalis Z, Tornai T, Altorjay I, Tornai I, Udvardy M, Fechner K, Jacobsen S, Teegen B, Sumegi A, Veres G, Lakatos PL, Kappelmayer J, Antal-Szalmas P.

J Hepatol. 2013 Sep;59(3):457-66. doi: 10.1016/j.jhep.2013.04.018. Epub 2013 Apr 29.

PMID:
23639483
11.

Catheter-directed thrombolysis in inflammatory bowel diseases: report of a case.

Ilonczai P, Tóth J, Tóth L, Altorjay I, Boda Z, Palatka K.

World J Gastroenterol. 2012 Sep 14;18(34):4791-3.

12.

Management of peptic ulcer bleeding in different case volume workplaces: results of a nationwide inquiry in hungary.

Rácz I, Kárász T, Lukács K, Rácz F, Kersák J, Wacha J, Szalóki T, Szász M, Gyenes I, Altorjay I.

Gastroenterol Res Pract. 2012;2012:956434. doi: 10.1155/2012/956434. Epub 2012 Sep 5.

13.

[Hungarian data on inflammatory bowel diseases: analytical data on ulcerative colistis].

Miheller P, Nagy F, Palatka K, Altorjay I, Horváth G, Lőrinczy K, Újszászy L, Virányi Z, Szepes A, Molnár T, Farkas K, Szepes Z, Nyári T, Wittmann T, Tulassay Z.

Orv Hetil. 2012 May 6;153(18):702-12. doi: 10.1556/OH.2012.29361. Hungarian.

PMID:
22547465
14.

Acute phase proteins in the diagnosis and prediction of cirrhosis associated bacterial infections.

Papp M, Vitalis Z, Altorjay I, Tornai I, Udvardy M, Harsfalvi J, Vida A, Kappelmayer J, Lakatos PL, Antal-Szalmas P.

Liver Int. 2012 Apr;32(4):603-11. doi: 10.1111/j.1478-3231.2011.02689.x. Epub 2011 Dec 6.

PMID:
22145664
15.

Anti-TNF-alpha antibody (infliximab) therapy supports the recovery of eNOS and VEGFR2 protein expression in endothelial cells.

Altorjay I, Veréb Z, Serfozo Z, Bacskai I, Bátori R, Erdodi F, Udvardy M, Sipka S, Lányi Á, Rajnavölgyi É, Palatka K.

Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):323-35.

PMID:
21658307
16.

Phenotypic polymorphism of haptoglobin: a novel risk factor for the development of infection in liver cirrhosis.

Vitalis Z, Altorjay I, Tornai I, Palatka K, Kacska S, Palyu E, Tornai D, Udvardy M, Harsfalvi J, Dinya T, Veres G, Lakatos PL, Papp M.

Hum Immunol. 2011 Apr;72(4):348-54. doi: 10.1016/j.humimm.2011.01.008. Epub 2011 Jan 21.

PMID:
21262313
17.

Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease.

Tromm A, Bunganič I, Tomsová E, Tulassay Z, Lukáš M, Kykal J, Bátovský M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Stimac D, Schäffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R; International Budenofalk Study Group.

Gastroenterology. 2011 Feb;140(2):425-434.e1; quiz e13-4. doi: 10.1053/j.gastro.2010.11.004. Epub 2010 Nov 9.

PMID:
21070781
18.

NKX2-3 and IRGM variants are associated with disease susceptibility to IBD in Eastern European patients.

Meggyesi N, Kiss LS, Koszarska M, Bortlik M, Duricova D, Lakatos L, Molnar T, Leniček M, Vítek L, Altorjay I, Papp M, Tulassay Z, Miheller P, Papp J, Tordai A, Andrikovics H, Lukas M, Lakatos PL.

World J Gastroenterol. 2010 Nov 7;16(41):5233-40.

19.

Presence of anti-microbial antibodies in liver cirrhosis--a tell-tale sign of compromised immunity?

Papp M, Norman GL, Vitalis Z, Tornai I, Altorjay I, Foldi I, Udvardy M, Shums Z, Dinya T, Orosz P, Lombay B Jr, Par G, Par A, Veres G, Csak T, Osztovits J, Szalay F, Lakatos PL.

PLoS One. 2010 Sep 23;5(9):e12957. doi: 10.1371/journal.pone.0012957.

20.

Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease.

Lakatos PL, Kiss LS, Palatka K, Altorjay I, Antal-Szalmas P, Palyu E, Udvardy M, Molnar T, Farkas K, Veres G, Harsfalvi J, Papp J, Papp M.

Inflamm Bowel Dis. 2011 Mar;17(3):767-77. doi: 10.1002/ibd.21402. Epub 2010 Sep 23.

PMID:
20865702
21.

Mannose-binding lectin deficiency confers risk for bacterial infections in a large Hungarian cohort of patients with liver cirrhosis.

Altorjay I, Vitalis Z, Tornai I, Palatka K, Kacska S, Farkas G, Udvardy M, Harsfalvi J, Dinya T, Orosz P, Lombay B Jr, Par G, Par A, Csak T, Osztovits J, Szalay F, Csepregi A, Lakatos PL, Papp M.

J Hepatol. 2010 Sep;53(3):484-91. doi: 10.1016/j.jhep.2010.03.028. Epub 2010 Jun 2.

PMID:
20605050
22.

Mannose-binding lectin level and deficiency is not associated with inflammatory bowel diseases, disease phenotype, serology profile, and NOD2/CARD15 genotype in a large Hungarian cohort.

Papp M, Lakatos PL, Harsfalvi J, Farkas G, Palatka K, Udvardy M, Molnar T, Farkas K, Nagy F, Veres G, Lakatos L, Kovacs A, Dinya T, Kocsis AK, Papp J; Hungarian IBD Study Group, Altorjay I.

Hum Immunol. 2010 Apr;71(4):407-13. doi: 10.1016/j.humimm.2010.01.012. Epub 2010 Jan 26.

PMID:
20079790
23.

[Novel aspects in the pathogenesis of gastroesophageal reflux disease].

Pregun I, Herszényi L, Bakucz T, Banai J, Molnár L, Altorjay I, Orosz P, Csernay L, Tulassay Z.

Orv Hetil. 2009 Oct 11;150(41):1883-7. doi: 10.1556/OH.2009.28722. Hungarian.

PMID:
19801354
24.

Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe--a Hungarian nationwide observational study.

Miheller P, Lakatos PL, Horváth G, Molnár T, Szamosi T, Czeglédi Z, Salamon A, Czimmer J, Rumi G, Palatka K, Papp M, Jakab Z, Szabó A, Gelley A, Lakatos L, Barta Z, Balázs C, Rácz I, Zeher M, Döbrönte Z, Altorjay I, Hunyady B, Simon L, Papp J, Banai J, Nagy F, Lonovics J, Ujszászy L, Muzes G, Herszényi L, Tulassay Z.

BMC Gastroenterol. 2009 Sep 10;9:66. doi: 10.1186/1471-230X-9-66.

25.

Anti-microbial antibodies in celiac disease: trick or treat?

Papp M, Foldi I, Altorjay I, Palyu E, Udvardy M, Tumpek J, Sipka S, Korponay-Szabo IR, Nemes E, Veres G, Dinya T, Tordai A, Andrikovics H, Norman GL, Lakatos PL.

World J Gastroenterol. 2009 Aug 21;15(31):3891-900.

26.

Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study.

Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, Altorjay I, Feagan B, Riff D, Bernstein CN, Hommes D, Rutgeerts P, Cortot A, Gaspari M, Cheng M, Pearce T, Sands BE.

Inflamm Bowel Dis. 2010 Feb;16(2):233-42. doi: 10.1002/ibd.21038.

PMID:
19637334
27.

Gastroesophageal reflux disease: work-related disease?

Pregun I, Bakucz T, Banai J, Molnár L, Pavlik G, Altorjay I, Orosz P, Csernay L, Tulassay Z, Herszényi L.

Dig Dis. 2009;27(1):38-44. doi: 10.1159/000210102. Epub 2009 May 8.

PMID:
19439959
28.

Evaluation of the combined application of ethanol-fixed and formaldehyde-fixed neutrophil substrates for identifying atypical perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

Papp M, Altorjay I, Lakos G, Tumpek J, Sipka S, Dinya T, Palatka K, Veres G, Udvardy M, Lakatos PL.

Clin Vaccine Immunol. 2009 Apr;16(4):464-70. doi: 10.1128/CVI.00002-09. Epub 2009 Feb 4.

29.

Esophageal replacement using cryopreserved tracheal graft.

Juhász A, Szilágyi A, Mikó I, Altorjay I, Kecskés G, Altorjay A.

Dis Esophagus. 2008;21(5):468-72. doi: 10.1111/j.1442-2050.2007.00780.x.

PMID:
19125802
30.

Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort.

Lakatos PL, Altorjay I, Szamosi T, Palatka K, Vitalis Z, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Barta Z, Stocker W, Papp J, Veres G, Papp M; Hungarian IBD Study Group.

Inflamm Bowel Dis. 2009 Mar;15(3):365-74. doi: 10.1002/ibd.20778.

PMID:
18972554
31.

The 3'UTR NFKBIA variant is associated with extensive colitis in Hungarian IBD patients.

Szamosi T, Lakatos PL; Hungarian IBD Study Group, Szilvasi A, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Szabo O, Satori A, Tulassay Z, Miheller P, Horvath HC, Papp J, Tordai A, Andrikovics H.

Dig Dis Sci. 2009 Feb;54(2):351-9. doi: 10.1007/s10620-008-0351-6. Epub 2008 Aug 21.

PMID:
18716880
32.

ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients.

Lakatos PL, Szamosi T, Szilvasi A, Molnar E, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Tulassay Z, Miheller P, Papp J, Tordai A, Andrikovics H; Hungarian IBD Study Group.

Dig Liver Dis. 2008 Nov;40(11):867-73. doi: 10.1016/j.dld.2008.03.022. Epub 2008 May 22.

PMID:
18499543
33.

Interaction between seroreactivity to microbial antigens and genetics in Crohn's disease: is there a role for defensins?

Lakatos PL, Altorjay I, Mándi Y, Lakatos L, Tumpek J, Kovacs A, Molnar T, Tulassay Z, Miheller P, Palatka K, Szamosi T, Fischer S, Papp J; Hungarian IBD Study Group, Papp M.

Tissue Antigens. 2008 Jun;71(6):552-9. doi: 10.1111/j.1399-0039.2008.01049.x. Epub 2008 Apr 7.

PMID:
18397186
34.

Haptoglobin polymorphism: a novel genetic risk factor for celiac disease development and its clinical manifestations.

Papp M, Foldi I, Nemes E, Udvardy M, Harsfalvi J, Altorjay I, Mate I, Dinya T, Varvolgyi C, Barta Z, Veres G, Lakatos PL, Tumpek J, Toth L, Szathmari E, Kapitany A, Gyetvai A, Korponay-Szabo IR.

Clin Chem. 2008 Apr;54(4):697-704. doi: 10.1373/clinchem.2007.098780. Epub 2008 Feb 7.

35.

In vivo target sites of nitric oxide in photosynthetic electron transport as studied by chlorophyll fluorescence in pea leaves.

Wodala B, Deák Z, Vass I, Erdei L, Altorjay I, Horváth F.

Plant Physiol. 2008 Apr;146(4):1920-7. doi: 10.1104/pp.107.110205. Epub 2008 Feb 1.

36.

New serological markers for inflammatory bowel disease are associated with earlier age at onset, complicated disease behavior, risk for surgery, and NOD2/CARD15 genotype in a Hungarian IBD cohort.

Papp M, Altorjay I, Dotan N, Palatka K, Foldi I, Tumpek J, Sipka S, Udvardy M, Dinya T, Lakatos L, Kovacs A, Molnar T, Tulassay Z, Miheller P, Norman GL, Szamosi T, Papp J; Hungarian IBD Study Group, Lakatos PL.

Am J Gastroenterol. 2008 Mar;103(3):665-81. Epub 2007 Nov 28.

PMID:
18047543
37.

NOD1 gene E266K polymorphism is associated with disease susceptibility but not with disease phenotype or NOD2/CARD15 in Hungarian patients with Crohn's disease.

Molnar T, Hofner P, Nagy F, Lakatos PL, Fischer S, Lakatos L, Kovacs A, Altorjay I, Papp M, Palatka K, Demeter P, Tulassay Z, Nyari T, Miheller P, Papp J, Mandi Y, Lonovics J; Hungarian IBD Study Group.

Dig Liver Dis. 2007 Dec;39(12):1064-70. Epub 2007 Oct 26.

PMID:
17964870
38.

ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgeryin Hungarian patients with inflammatory bowel diseases.

Fischer S, Lakatos PL; Hungarian IBD Study Group, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Szilvasi A, Tulassay Z, Osztovits J, Papp J, Demeter P, Schwab R, Tordai A, Andrikovics H.

Scand J Gastroenterol. 2007 Jun;42(6):726-33.

PMID:
17505995
39.

[Gastroesophageal variceal haemorrhage--new advances in pathophysiology].

Papp M, Udvardy M, Vitális Z, Tornai I, Altorjay I.

Orv Hetil. 2006 Feb 19;147(7):309-14. Review. Hungarian.

PMID:
17489158
40.

[Relevance of serologic studies in inflammatory bowel diseases].

Papp M, Altorjay I, Lakatos PL.

Orv Hetil. 2007 May 13;148(19):887-96. Review. Hungarian.

PMID:
17478404
41.

Utility of serological markers in inflammatory bowel diseases: gadget or magic?

Papp M, Norman GL, Altorjay I, Lakatos PL.

World J Gastroenterol. 2007 Apr 14;13(14):2028-36. Review.

42.

Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.

Papp M, Altorjay I, Norman GL, Shums Z, Palatka K, Vitalis Z, Foldi I, Lakos G, Tumpek J, Udvardy ML, Harsfalvi J, Fischer S, Lakatos L, Kovacs A, Bene L, Molnar T, Tulassay Z, Miheller P, Veres G, Papp J; Hungarian IBD Study Group, Lakatos PL.

Inflamm Bowel Dis. 2007 Aug;13(8):984-92.

PMID:
17417801
43.

[Prevention and treatment of esophageal variceal bleeding].

Vitális Z, Papp M, Tornai I, Altorjay I.

Orv Hetil. 2006 Dec 24;147(51):2455-63. Review. Hungarian.

PMID:
17378164
44.

Haptoglobin polymorphisms are associated with Crohn's disease, disease behavior, and extraintestinal manifestations in Hungarian patients.

Papp M, Lakatos PL; Hungarian IBD Study Group, Palatka K, Foldi I, Udvardy M, Harsfalvi J, Tornai I, Vitalis Z, Dinya T, Kovacs A, Molnar T, Demeter P, Papp J, Lakatos L, Altorjay I.

Dig Dis Sci. 2007 May;52(5):1279-84. Epub 2007 Mar 15.

PMID:
17357835
45.

[Haptoglobin polymorphism in patients with inflammatory bowel diseases].

Papp M, Lakatos PL; Hungarian IBD Study Group, Palatka K, Földi I, Udvardy M, Hársfalvi J, Tornai I, Vitális Z, Dinya T, Kovács A, Molnár T, Demeter P, Papp J, Lakatos L, Altorjay I.

Orv Hetil. 2006 Sep 10;147(36):1745-50. Hungarian.

PMID:
17087019
46.

Morphological changes in the lower esophageal sphincter influencing the result of antireflux surgical interventions in chronic gastroesophageal reflux disease.

Altorjay A, Szilagyi A, Arato G, Balazs P, Juhasz A, Kecskes G, Altorjay I, Kiss J, Nagy P.

Hepatogastroenterology. 2006 May-Jun;53(69):342-7.

PMID:
16795968
47.

DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease.

Lakatos PL, Fischer S, Claes K, Kovacs A, Molnar T, Altorjay I, Demeter P, Tulassay Z, Palatka K, Papp M, Rutgeerts P, Szalay F, Papp J, Vermeire S, Lakatos L; Hungarian IBD Study Group.

Inflamm Bowel Dis. 2006 May;12(5):362-8.

PMID:
16670524
48.

Effect of IBD sera on expression of inducible and endothelial nitric oxide synthase in human umbilical vein endothelial cells.

Palatka K, Serfozo Z, Veréb Z, Bátori R, Lontay B, Hargitay Z, Nemes Z, Udvardy M, Erdodi F, Altorjay I.

World J Gastroenterol. 2006 Mar 21;12(11):1730-8.

49.

Changes in the expression and distribution of the inducible and endothelial nitric oxide synthase in mucosal biopsy specimens of inflammatory bowel disease.

Palatka K, Serfozo Z, Veréb Z, Hargitay Z, Lontay B, Erdodi F, Bánfalvi G, Nemes Z, Udvardy M, Altorjay I.

Scand J Gastroenterol. 2005 Jun;40(6):670-80.

PMID:
16036527
50.

The place of gastro-jejuno-duodenal interposition following limited esophageal resection.

Altorjay A, Kiss J, Paál B, Tihanyi Z, Luka F, Farsang Z, Asztalos I, Altorjay I.

Eur J Cardiothorac Surg. 2005 Aug;28(2):296-300.

PMID:
15963730

Supplemental Content

Loading ...
Support Center